Journal Article

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study

McKenna, S., Griffiths, R., Carroll, R., Tsang, C., Hurst, M., Groves, L., Fife, K., Sharma, A., Sugrue, D., Waddell, T., Dhokia, P., Houghton, J.

2022

Overview

Background The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma (aRCC). However, supporting real-world data is lacking. This study investigated characteristics, treatment sequences and clinical outcomes of patients who received nivolumab monotherapy for previously treated aRCC in the UK. Methods This was a retrospective cohort study of aRCC patients treated with nivolumab at second line or later (2L +) at 4 UK oncology centres. Eligible patients commenced nivolumab (index date) between 01 March 2016 and 30 June 2018 (index period). Study data were extracted from medical records using an electronic case report form. Data cut-off (end of follow-up) was 31 May 2019. Results In total, 151 patients were included with median follow-up of 15.2 months. Mean age was 66.9 years, male preponderance (72.2%), and mostly Eastern Cooperative Oncology Group performance status grade 0–1 (71.5%). Amongst 112 patients with a known International Metastatic RCC Database Consortium score, distribution between favourable, intermediate, and poor risk categories was 20.5%, 53.6%, and 25.9% respectively. The majority of patients ( n  = 109; 72.2%) received nivolumab at 2L, and these patients had a median overall survival (OS) of 23.0 months [95% confidence interval: 17.2, not reached]. All patients who received nivolumab at 2L had received TKIs at 1L. Amongst the 42 patients (27.8%) who received nivolumab in third line or later (3L +) the median OS was 12.4 months [95% CI: 8.8, 23.2]. The most common reasons for nivolumab discontinuation were disease progression (2L: 61.2%; 3L: 68.8%) and adverse events (2L: 34.7%; 3L: 28.1%). Conclusion This study provides real-world evidence on the characteristics, treatment sequences, and outcomes of aRCC patients who received 2L + nivolumab monotherapy in the UK. Nivolumab-specific survival outcomes were similar to those achieved in the CheckMate 025 trial.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Aged / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Apoptosis / Biomedical and Life Sciences / Biomedicine / Cancer Research / Carcinoma, Renal cell / Carcinoma, Renal Cell - pathology / Clinical medicine / Clinical trials / Cohort analysis / Data collection / Drug therapy / Health Promotion and Disease Prevention / Humans / Immunotherapy / Kidney cancer / Kidney Neoplasms - pathology / Male / Medical record review / Medical records / Medicine/Public Health / Metastases / Metastasis / Monoclonal antibodies / Nivolumab / Nivolumab - therapeutic use / Oncology / Patient outcomes / Patients / Real-world evidence / Renal cell carcinoma / Retrospective Studies / Statistics / Surgical Oncology / Survival / Targeted cancer therapy / United Kingdom - epidemiology